Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03395080 · OUTCOME

Overall Survival (OS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma · Source last updated 2025-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline to study completion (maximum 17.6 months)

What was measured

Overall Survival (OS) is defined as the time from first dose of study drug until date of death due to any cause.

Analysis population: Full Analysis Set (FAS), all subjects who received any amount of DKN-01.

Groups in this outcome

DKN-01 Monotherapy in Recurrent EEC

300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.

DKN-01 + Paclitaxel in Recurrent EEC

300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.

DKN-01 Monotherapy in Recurrent EOC

300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.

DKN-01 + Paclitaxel in Recurrent EOC

300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.

DKN-01 300mg Monotherapy in Carcinosarcoma

300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.

DKN-01 600mg Monotherapy in Carcinosarcoma

600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.

DKN-01 300mg + Paclitaxel in Carcinosarcoma

300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.

DKN-01 600mg + Paclitaxel in Carcinosarcoma

600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
DKN-01 Monotherapy in Recurrent EEC29
DKN-01 + Paclitaxel in Recurrent EEC24
DKN-01 Monotherapy in Recurrent EOC14
DKN-01 + Paclitaxel in Recurrent EOC19
DKN-01 300mg Monotherapy in Carcinosarcoma1
DKN-01 600mg Monotherapy in Carcinosarcoma8
DKN-01 300mg + Paclitaxel in Carcinosarcoma4
DKN-01 600mg + Paclitaxel in Carcinosarcoma12

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
DKN-01 Monotherapy in Recurrent EEC12.2Not reported4.6NANA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
DKN-01 + Paclitaxel in Recurrent EEC10.1Not reported6.513.6Not reported
DKN-01 Monotherapy in Recurrent EOC10.8Not reported5.717.6Not reported
DKN-01 + Paclitaxel in Recurrent EOC11.9Not reported6.6NANA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
DKN-01 300mg Monotherapy in CarcinosarcomaNANot reportedNANAData are not estimable due to insufficient number of participants with events.
DKN-01 600mg Monotherapy in Carcinosarcoma8.4Not reported1.3NANA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
DKN-01 300mg + Paclitaxel in Carcinosarcoma7.3Not reported5.3NANA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
DKN-01 600mg + Paclitaxel in Carcinosarcoma5.7Not reported1.6NANA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
        group Id
        OG000
        lower Limit
        4.6
        upper Limit
        NA
        value
        12.2
      2. group Id
        OG001
        lower Limit
        6.5
        upper Limit
        13.6
        value
        10.1
      3. group Id
        OG002
        lower Limit
        5.7
        upper Limit
        17.6
        value
        10.8
      4. comment
        NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
        group Id
        OG003
        lower Limit
        6.6
        upper Limit
        NA
        value
        11.9
      5. comment
        Data are not estimable due to insufficient number of participants with events.
        group Id
        OG004
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      6. comment
        NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
        group Id
        OG005
        lower Limit
        1.3
        upper Limit
        NA
        value
        8.4
      7. comment
        NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
        group Id
        OG006
        lower Limit
        5.3
        upper Limit
        NA
        value
        7.3
      8. comment
        NA=Not Estimable. Data are not estimable due to insufficient number of participants with events.
        group Id
        OG007
        lower Limit
        1.6
        upper Limit
        NA
        value
        5.7
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    2. group Id
      OG001
      value
      24
    3. group Id
      OG002
      value
      14
    4. group Id
      OG003
      value
      19
    5. group Id
      OG004
      value
      1
    6. group Id
      OG005
      value
      8
    7. group Id
      OG006
      value
      4
    8. group Id
      OG007
      value
      12
    units
    Participants
description
Overall Survival (OS) is defined as the time from first dose of study drug until date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.
    id
    OG000
    title
    DKN-01 Monotherapy in Recurrent EEC
  2. description
    300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG001
    title
    DKN-01 + Paclitaxel in Recurrent EEC
  3. description
    300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.
    id
    OG002
    title
    DKN-01 Monotherapy in Recurrent EOC
  4. description
    300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG003
    title
    DKN-01 + Paclitaxel in Recurrent EOC
  5. description
    300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.
    id
    OG004
    title
    DKN-01 300mg Monotherapy in Carcinosarcoma
  6. description
    600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.
    id
    OG005
    title
    DKN-01 600mg Monotherapy in Carcinosarcoma
  7. description
    300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG006
    title
    DKN-01 300mg + Paclitaxel in Carcinosarcoma
  8. description
    600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG007
    title
    DKN-01 600mg + Paclitaxel in Carcinosarcoma
param Type
MEDIAN
population Description
Full Analysis Set (FAS), all subjects who received any amount of DKN-01.
reporting Status
POSTED
time Frame
Baseline to study completion (maximum 17.6 months)
title
Overall Survival (OS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice